Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 18, 1999

View Archived Issues

CLASS study evaluates clomethiazole in acute stroke patients

Teijin in-licenses novel asthma therapeutic from Byk Gulden

SmithKline Beecham describes novel compounds for depression and other CNS disorders

Eradication of H. pylori has dubious therapeutic effect in patients with nonulcer dyspepsia

Selective dopamine D3 receptor modulators synthesized at SB

Takeda develops compounds that induce and/or enhance cell differentiation

Research at Jouveinal leads to potent and selective PDE4 inhibitors

More PDE5 inhibitors in the Pfizer pipeline

Novel antidiabetic agents in development at Novo Nordisk

CPMP approves angiotensin II antagonist for management of hypertension

Cortex licenses Ampakine rights to Organon

Orphan drug for iron overload offered for licensing by Biomedical Frontiers

FDA approves Pletal for intermittent claudication

Warner-Lambert updates U.S. status of Rezulin

MIST study provides further evidency of zanamivir's efficacy and safety

Epitope-based HIV vaccines show promise according to results from studies in primates

Novartis initiates phase III trial of schizophrenia treatment

XTL's first fully human MAb heading for clinical trials this quarter

Greater antitumor efficacy and less toxicity obtained with liposomal cisplatin

Beraprost to enter clinical trials in North America

Milestone reached by Cadus in drug discovery collaboration with SmithKline Beecham

Biogen: Q4 and FY 1998 highlights

Tenth HuMAb-Mouse licensing agreement for Medarex: Immunex granted broad rights

Palatin and Nihon Medi-Physics intend to develop radiopharmaceutical products

Antitumor candidate originating in Kazakstan slated for development in U.S. and other countries

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...